The race for cures: a month completely crazy for chloroquine

La course aux remèdes: un mois complètement fou pour la chloroquine

The last few weeks have been strong in the twists and turns in the folder of the chloroquine, the withdrawal of a study has raised the passions and the United States have put an end to its use.

Latest development in the running, the Food and Drug Administration (FDA) has withdrawn its authorization of emergency use of the drug.

It had been given in march, when the president, Donald Trump made the apology. The FDA has finally concluded Monday that the molecule presents too much of a risk without proven benefits.

This is a result of months completely mad marked by an article published on 22 may in the prestigious british medical journal The Lancet.

The authors of the research concluded that hydroxychloroquine was not only ineffective against the COVID-19, but it was also dangerous to some patients.

Its publication has caused a shock wave pushing the world health Organization to suspend any clinical trial on chloroquine and its derivative hydroxychloroquine, everywhere on the planet.

The study, however, drew the ire of the defenders of the molecule, which the Pr Didier Raoult. Not chewing not his words, he had called it ” half-assed “.

After the mobilization of the scientific community, which put in doubt the methodology, three of the authors of the paper retracted and it was finally removed.

The divergent opinions

Around the world, the chloroquine has nonetheless continued to diverge.

Two German studies that had been interrupted, are about to resume.

Same thing for the long-awaited european study Discovery, which had been treading water because of the too low number of patients enrolled.

In Brazil, in may, the government has recommended the use of the drug for those with mild disease.

In Belgium, 5,000 patients have been treated with the molecule since the beginning of the pandemic.

The british study Recovery, performed on thousands of patients, has been arrested, in the absence of positive effect.

In Quebec, the national Institute for excellence in health and social services, is adamant : he does not have sufficient scientific evidence to recommend the use of the drug outside of a research protocol.

The events are scrambling

May 22,

Publication of a study in The Lancet, which concludes that the ineffectiveness of hydroxychloroquine and its dangerousness

May 23,

Publication of a letter signed by 120 scientists questioning the methods used in the study

May 25,

Suspension by the world health Organization
health organization (WHO) of all clinical trials on chloroquine

3 June

Resumption of trials announced by the WHO

5 June

Three of the authors of the study retracted, which leads to the withdrawal of the article from the journal

June 15,

Withdrawal of the authorization of emergency use of the Food and Drug Administration (FDA)

This thinks of that the doc Béliveau

Chloroquine : Despite all the hubbub surrounding the chloroquine, the trend that emerges is that the use of this drug (or its derivative hydroxychloroquine) do not present advantages for the treatment of the COVID-19. In addition, the results of the randomized clinical trial conducted by McGill University, published in the 3 June in the New England Journal of Medicine, indicate that the drug does not prevent the development of the disease in people who had been in close contact with a patient COVID-19.

Share Button